Multicentric Castleman Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLT113 MIFTS: 51	Multicentric Castleman Disease Categories: Rare diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease ¹² ⁵³

Plasmablastic Multicentric Castleman Disease ¹² ⁵³

Multicentric Giant Lymph Node Hyperplasia ¹² ⁵³

Multi-Centric Castleman's Disease ⁴⁴ ⁷³

Pmcd ¹² ⁵³

Mcd ¹² ⁵³

Multicentric Plasma Cell Variant of Castleman's Disease ⁵³

Idiopathic Multicentric Castleman's Disease ⁵³

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Benign neoplasms

Benign neoplasm of other and unspecified sites

Benign neoplasm: Lymph nodes

External Ids:

Disease Ontology ¹² DOID:0111152

ICD10 ³³ D36.0

MeSH ⁴⁴ C537372

UMLS ⁷³ C1334815

Sources

Summaries for Multicentric Castleman Disease

NIH Rare Diseases : ⁵³ Multicentric Castleman disease (MCD) is a rare condition that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and affects multiple sets of lymph nodes and other tissues throughout the body (as opposed to unicentric Castleman disease which has more "localized" effects). The signs and symptoms of MCD are often nonspecific and blamed on other, more common conditions. They can vary but may include fever; weight loss; fatigue; night sweats; enlarged lymph nodes; nausea and vomiting; and an enlarged liver or spleen. The exact underlying cause is unknown. Treatment may involve immunotherapy, chemotherapy, corticosteroid medications and/or anti-viral drugs.

MalaCards based summary : Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to castleman disease and pneumonia, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and spleen, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : ¹² A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Sources

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)

#	Related Disease	Score	Top Affiliating Genes
1	castleman disease	33.5	CRP IL6 KRT15
2	pneumonia	30.2	CRP IL10 IL5 IL6
3	hematopoietic stem cell transplantation	30.2	IFNG IL10 IL6
4	lymphoma, non-hodgkin, familial	29.1	ABCB1 BCL6 IGH PAX5
5	systemic lupus erythematosus	28.9	CRP F3 IFNG IL10 IL6
6	kaposi sarcoma	12.0
7	malonyl-coa decarboxylase deficiency	11.8
8	macular dystrophy, corneal	11.8
9	multiple carboxylase deficiency	11.8
10	metaphyseal chondrodysplasia, schmid type	11.7
11	human herpesvirus 8	11.5
12	unicentric castleman disease	11.2
13	cold agglutinin disease	10.9	CRP IL6
14	cryopyrin-associated periodic syndrome	10.9	CRP IL6
15	eye lymphoma	10.9	IL10 IL6
16	angioimmunoblastic lymphadenopathy with dysproteinemia	10.9	IL5 IL6
17	bagassosis	10.8	IL5 IL6
18	cardiogenic shock	10.8	CRP IL6
19	acute transverse myelitis	10.8	IL10 IL6
20	acute cholangitis	10.8	CRP IL6
21	neutrophilia, hereditary	10.8	CRP IL6
22	uremic pruritus	10.8	CRP IL6
23	chronic meningitis	10.7	CRP IL5
24	acute pyelonephritis	10.7	CRP IL10 IL6
25	funisitis	10.7	IL10 IL6
26	hemorrhagic fever with renal syndrome	10.7	CRP IL10 IL6
27	leptospirosis	10.7	CRP IL10 IL6
28	pyelonephritis	10.7	CRP IL10 IL6
29	appendicitis	10.7	CRP IL10 IL6
30	spinal disease	10.7	CRP IL6
31	mesenteric lymphadenitis	10.7	CRP IL5 IL6
32	bacterial meningitis	10.7	CRP IL10 IL6
33	endocarditis	10.7	CRP IL10 IL6
34	radiculopathy	10.7	IL10 IL5 IL6
35	peritonitis	10.6	CRP IL10 IL6
36	kawasaki disease	10.6	CRP IL10 IL6
37	cow milk allergy	10.6	IL10 IL5
38	acute pancreatitis	10.6	CRP IL10 IL6
39	blue toe syndrome	10.6	CRP F3
40	acquired hemophilia a	10.6	F3 F8
41	fournier gangrene	10.6	F3 F8
42	angina pectoris	10.6	CRP F3 IL6
43	nodular lymphocyte predominant hodgkin lymphoma	10.6	BCL6 PAX5
44	acquired hemophilia	10.6	F3 F8
45	intermediate coronary syndrome	10.6	CRP F3 IL6
46	eosinophilic fasciitis	10.6	IFNG IL5
47	hyperlucent lung	10.5	IFNG IL10
48	scrub typhus	10.5	CRP F3 IL10
49	thrombocytosis	10.5	CRP F3 IL6
50	b-cell growth factor	10.5	IFNG IL6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:

Sources

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:

fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.14	F3 IL6 F8 IL21 ID1 ABCB1
2	homeostasis/metabolism	MP:0005376	10.11	IL5 IL10 F3 F8 IL6 IL21
3	immune system	MP:0005387	10.1	IL6 F8 IL21 ID1 ABCB1 PAX5
4	cardiovascular system	MP:0005385	10.06	F3 IL10 IL6 ID1 ABCB1 BCL6
5	digestive/alimentary	MP:0005381	9.98	IL5 IL10 IL6 ID1 KRT15 ABCB1
6	liver/biliary system	MP:0005370	9.8	IL10 IL6 ID1 ABCB1 BCL6 IFNG
7	neoplasm	MP:0002006	9.7	F3 IL6 ID1 PAX5 IFNG IL5
8	reproductive system	MP:0005389	9.56	IL5 IL10 F8 IL6 ID1 ABCB1
9	respiratory system	MP:0005388	9.17	IL5 IL10 F3 IL6 ID1 BCL6

Sources

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ganciclovir

Approved, Investigational

Phase 4,Phase 2

82410-32-0

3454

Valganciclovir

Approved, Investigational

Phase 4,Phase 2

175865-60-8

64147

Anti-Infective Agents

Phase 4,Phase 2,Phase 1

Antiviral Agents

Phase 4,Phase 2

Ganciclovir triphosphate

Phase 4,Phase 2

Siltuximab

Approved, Investigational

Phase 2,Phase 1,Early Phase 1

541502-14-1

Cyclophosphamide

Approved, Investigational

Phase 2,Phase 1

50-18-0, 6055-19-2

2907

Prednisone

Approved, Vet_approved

Phase 2,Phase 1

53-03-2

5865

Zidovudine

Approved

Phase 2

30516-87-1

35370

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Doxorubicin

Approved, Investigational

Phase 2,Phase 1

23214-92-8

31703

Etoposide

Approved

Phase 2,Phase 1

33419-42-0

36462

Everolimus

Approved

Phase 2

159351-69-6

6442177

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

rituximab

Approved

Phase 2,Phase 1

174722-31-7

10201696

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030 46835353

Vincristine

Approved, Investigational

Phase 2,Phase 1

2068-78-2, 57-22-7

5978

Pomalidomide

Approved

Phase 1, Phase 2

19171-19-8

Doxil

Approved June 1999

Phase 2,Phase 1

31703

Analgesics

Phase 2

Antibodies

Phase 2,Phase 1,Early Phase 1

Antibodies, Monoclonal

Phase 2,Phase 1,Early Phase 1

Antipyretics

Phase 2

Histamine Antagonists

Phase 2

Histamine H1 Antagonists

Phase 2

Immunoglobulins

Phase 2,Phase 1,Early Phase 1

Pharmaceutical Solutions

Phase 2

Alkylating Agents

Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 2,Phase 1

Anti-Bacterial Agents

Phase 2,Phase 1

Anti-Inflammatory Agents

Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 2,Phase 1

Antineoplastic Agents, Hormonal

Phase 2,Phase 1

Antirheumatic Agents

Phase 2,Phase 1

glucocorticoids

Phase 2,Phase 1

Hormone Antagonists

Phase 2,Phase 1

Hormones

Phase 2,Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2,Phase 1

Immunosuppressive Agents

Phase 2,Phase 1

Anti-HIV Agents

Phase 2

Antimetabolites

Phase 2

Anti-Retroviral Agents

Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 2

Reverse Transcriptase Inhibitors

Phase 2

Adjuvants, Immunologic

Phase 2

Antibiotics, Antitubercular

Phase 2,Phase 1

Antifungal Agents

Phase 2

Antimitotic Agents

Phase 2,Phase 1

Interventional clinical trials:

(show all 19)

#	Name	Status	NCT ID	Phase	Drugs
1	Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease	Withdrawn	NCT00361933	Phase 4	Valganciclovir
2	A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease	Completed	NCT01024036	Phase 2	Siltuximab;Placebo;Best Supportive Care (BSC)
3	A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease	Completed	NCT01400503	Phase 2	Siltuximab
4	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis	Completed	NCT00132015	Phase 2	tanespimycin
5	TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial	Recruiting	NCT03043105	Phase 2	Thalidomide, cyclophosphamide and prednisone
6	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Recruiting	NCT01441063	Phase 2	Zidovudine;Tocilizumab;Valganciclovir (VGC)
7	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	Recruiting	NCT00092222	Phase 2	Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
8	Siltuximab in Schizophrenia	Recruiting	NCT02796859	Phase 1, Phase 2	Siltuximab;normal saline
9	Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy	Terminated	NCT00127569	Phase 2	Rituximab
10	Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas	Withdrawn	NCT02228512	Phase 1, Phase 2	Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
11	A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment	Completed	NCT01183598	Phase 1	tocilizumab [RoActemra/Actemra]
12	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	Recruiting	NCT02659930	Phase 1	liposomal doxorubicin;pomalidomide
13	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Terminated	NCT02109224	Phase 1	Ibrutinib
14	Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials	Completed	NCT00695422
15	Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer	Recruiting	NCT00006518
16	Unlock the Cell: Castleman's Disease Flow Cytometry Study	Recruiting	NCT02853968
17	Castleman Disease Collaborative Network Biobank	Recruiting	NCT02871050
18	International Registry for Patients With Castleman Disease	Recruiting	NCT02817997
19	Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis	Withdrawn	NCT02805868	Early Phase 1

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Sources

Genetic Tests for Multicentric Castleman Disease

Sources

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

⁴¹

Lymph Node, Liver, Spleen, B Cells, Bone, Bone Marrow, T Cells

Sources

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 153)

#	Title	Authors	Year
1	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. ( 29732477 )	Dong Y....Li J.	2018
2	The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 29684500 )	Kurose N....Yamada S.	2018
3	Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )	Lurain K....Uldrick T.S.	2018
4	Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )	Patel A.S....Goswami N.D.	2018
5	Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. ( 29675946 )	Pierson S.K....Fajgenbaum D.C.	2018
6	Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )	Li F....Ling Y.	2018
7	Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case reporta8c. ( 29701172 )	Yamada Y....Masaki T.	2018
8	Late-onset skin involvement on the forehead in multicentric Castleman disease. ( 28244070 )	Sato K....Shimizu H.	2017
9	Multicentric Castleman disease: consensus at last? ( 28336727 )	Said J.	2017
10	EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity. ( 29198143 )	Shivane A....Smith M.E.F.	2017
11	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. ( 28087540 )	Fajgenbaum D.C....Lim M.S.	2017
12	TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. ( 28135567 )	Srkalovic G....Fajgenbaum D.C.	2017
13	Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. ( 28845155 )	Polizzotto M.N....Yarchoan R.	2017
14	Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report. ( 28501028 )	Basnayake B.M.D.B....Ameer A.M.	2017
15	Thin-section Computed Tomographic Findings of Multicentric Castleman Disease Changing Over 10 Years. ( 28914746 )	Tashiro H....Sueoka-Aragane N.	2017
16	Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. ( 28143881 )	Pria A.D....Bower M.	2017
17	(18)F-FDG PET/CT in multicentric Castleman disease: a case report. ( 26904580 )	Ding Q....Yang L.	2016
18	A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. ( 26948831 )	Kantarci F.E....SuyanA+ E.	2016
19	Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. ( 26980221 )	Fujiwara S....Nosaka K.	2016
20	TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. ( 26663467 )	Carbone A....Pantanowitz L.	2016
21	Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion. ( 26614115 )	Akman A.O....Cakar N.	2016
22	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. ( 26634298 )	Fajgenbaum D.C....Kurzrock R.	2016
23	Human Herpesvirus Type 8-positive Multicentric Castleman Disease. ( 27133959 )	Melikyan A.L....Savchenko V.G.	2016
24	Multicentric Castleman disease: Where are we now? ( 27296355 )	Wang H.W....Jaffe E.S.	2016
25	Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )	London J....Galicier L.	2016
26	Unicentric versus Multicentric Castleman Disease. ( 27618317 )	Frazier A.A.	2016
27	Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. ( 26598921 )	Zoshima T....Kawano M.	2016
28	Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. ( 26805758 )	Iwaki N....Sato Y.	2016
29	Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. ( 27741115 )	Flahault A....El Karoui K.	2016
30	Bone marrow manifestations in multicentric Castleman disease. ( 26817834 )	Ibrahim H.A....Naresh K.N.	2016
31	iNKT and memory B cells alterations in HHV-8 multicentric Castleman disease. ( 28060720 )	Sbihi Z....Carcelain G.	2016
32	Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. ( 25093377 )	Alzahrani M....Leitch H.A.	2015
33	Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. ( 25900626 )	Koenig G....Peker D.	2015
34	Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. ( 26137030 )	Song K....Li M.	2015
35	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. ( 26124203 )	Casper C....van Rhee F.	2015
36	Siltuximab for Multicentric Castleman Disease-Letter. ( 26473194 )	Teipel R....Platzbecker U.	2015
37	18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. ( 25828248 )	Polizzotto M.N....Yarchoan R.	2015
38	FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. ( 25601959 )	Deisseroth A....Pazdur R.	2015
39	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. ( 26327301 )	van Rhee F....Kurzrock R.	2015
40	Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. ( 26242311 )	Gopal S....Fedoriw Y.	2015
41	Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. ( 25208471 )	Casper C....Reynolds M.W.	2015
42	Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease. ( 26756053 )	Debord C....Eveillard M.	2015
43	Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. ( 26666616 )	Iijima T....Ubara Y.	2015
44	KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. ( 24771491 )	Carbone A....Vaccher E.	2015
45	(Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence). ( 26490523 )	Goyal G....Vivekanandan R.	2015
46	Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. ( 26394632 )	Lyseng-Williamson K.A.	2015
47	Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. ( 24387011 )	Robinson D....Van de Velde H.	2014
48	Multicentric Castleman disease presenting with fever. ( 25282064 )	Smith C....Asturias E.J.	2014
49	Successful single-lung transplantation for multicentric Castleman disease. ( 25193223 )	Morimura Y....Date H.	2014
50	Siltuximab for multicentric Castleman disease. ( 25110138 )	Liu Y.C....van Rhee F.	2014

Sources

Genes for Multicentric Castleman Disease

Genes related to Multicentric Castleman Disease (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	IL6	Interleukin 6	Protein Coding	18.06	GeneCards inferred via : Publications (show sections)
2	CRP	C-Reactive Protein	Protein Coding	17.44	GeneCards inferred via : Publications (show sections)
3	IL10	Interleukin 10	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
4	KRT15	Keratin 15	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
5	IL5	Interleukin 5	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
6	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
7	PAX5	Paired Box 5	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
8	F8	Coagulation Factor VIII	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
9	F3	Coagulation Factor III, Tissue Factor	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
10	BCL6	B Cell CLL/Lymphoma 6	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
11	IL21	Interleukin 21	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
12	IFNG	Interferon Gamma	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
13	CCL4	C-C Motif Chemokine Ligand 4	Protein Coding	7.09	GeneCards inferred via : Publications (show sections)
14	ID1	Inhibitor Of DNA Binding 1, HLH Protein	Protein Coding	7.09	GeneCards inferred via : Publications (show sections)
15	IGH	Immunoglobulin Heavy Locus	Protein Coding	7.09	GeneCards inferred via : Publications (show sections)

Sources

Variations for Multicentric Castleman Disease

Sources

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Sources

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 29)

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.22	BCL6 CCL4 IFNG IL10 IL5 IL6
2	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.65	ABCB1 IFNG IL10 IL21 IL5 IL6
3	NF-kappaB Signaling ⁴	12.43	BCL6 IFNG IL10 PAX5
4	Regulation of IFNA signaling ⁶⁶ Show member pathways Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Jak-STAT signaling pathway ³⁷	12.36	IFNG IL10 IL21 IL5 IL6
5	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.29	IFNG IL10 IL5 IL6
6	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ IL-6-type cytokine receptor ligand interactions ⁶⁶ Interleukin-6 family signaling ⁶⁶ Interleukin-6 signaling ⁶⁶ Th17 Differentiation Pathway ⁶⁵	12.12	IFNG IL10 IL21 IL6
7	Th17 cell differentiation ³⁷ Show member pathways Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	11.98	IFNG IL10 IL21 IL5 IL6
8	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.96	BCL6 IL10 IL6
9	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.91	CCL4 IFNG IL10 IL5 IL6
10	Interleukin-4 and 13 signaling ⁶⁶	11.86	BCL6 IL10 IL6
11	Amoebiasis ³⁷	11.77	IFNG IL10 IL6
12	Salmonella infection (KEGG) ³⁷	11.72	CCL4 IFNG IL6
13	Jak-Stat Signaling Pathway ⁶⁷	11.72	IFNG IL10 IL21 IL6
14	Glucocorticoid receptor regulatory network ¹	11.69	IFNG IL5 IL6
15	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.69	IFNG IL10 IL5 IL6
16	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.67	IFNG IL10 IL5
17	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.62	IFNG IL10 IL6
18	IL4-mediated signaling events ¹	11.54	BCL6 IL10 IL5
19	Lung fibrosis ¹	11.53	CCL4 IL5 IL6
20	Interleukin-10 signaling ⁶⁶	11.4	CCL4 IL10 IL6
21	Malaria ³⁷	11.39	IFNG IL10 IL6
22	Th2 Differentiation Pathway ⁶⁵	11.35	IFNG IL10 IL5
23	African trypanosomiasis ³⁷	11.18	IFNG IL10 IL6
24	Development and heterogeneity of the ILC family ¹	11.09	IFNG IL5 IL6
25	B Cell Development Pathways ⁶⁵	10.98	BCL6 IL10 IL21 PAX5
26	Overview of nanoparticle effects ¹	10.91	CRP IL6
27	OX40 Pathway ⁶⁴	10.85	IFNG IL10 IL5
28	ID signaling pathway ¹	10.83	ID1 PAX5
29	Cytokines and Inflammatory Response ¹	10.4	IFNG IL10 IL5 IL6

Sources

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.61	CCL4 CRP F3 F8 IFNG IL10
2	extracellular space	GO:0005615	9.28	CCL4 CRP F3 F8 IFNG IL10

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.83	CRP ID1 IFNG IL6
2	immune response	GO:0006955	9.73	CCL4 IFNG IL10 IL21 IL5 IL6
3	positive regulation of DNA binding transcription factor activity	GO:0051091	9.69	IL10 IL5 IL6
4	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.63	IFNG IL21 IL6
5	regulation of signaling receptor activity	GO:0010469	9.63	CCL4 IFNG IL10 IL21 IL5 IL6
6	humoral immune response	GO:0006959	9.58	IFNG IL6 PAX5
7	positive regulation of B cell proliferation	GO:0030890	9.54	BCL6 IL21 IL5
8	acute-phase response	GO:0006953	9.5	CRP F8 IL6
9	positive regulation of immunoglobulin secretion	GO:0051024	9.49	IL5 IL6
10	negative regulation of lipid storage	GO:0010888	9.48	CRP IL6
11	type 2 immune response	GO:0042092	9.43	BCL6 IL10
12	inflammatory response	GO:0006954	9.43	BCL6 CCL4 CRP IL10 IL5 IL6
13	cytokine-mediated signaling pathway	GO:0019221	9.1	BCL6 CCL4 F3 IL10 IL5 IL6

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine activity	GO:0005125	9.1	CCL4 IFNG IL10 IL21 IL5 IL6

Sources

Sources for Multicentric Castleman Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia